Drugs / VSV-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07260591 | Sep 2025 → Sep 2026 overdue | breast cancer, lung cancer, melanoma | The First Affiliated Hospital of Xinxiang Medical College | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VSV-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07260591 ↗ |
| Known as | VSV-02 Injection | “VSV-02 Injection is an oncolytic virus vaccine based on an attenuated Vesicular Stomatitis Virus (VSV) that is engineered to encode a CD3/PD-L1 bispecific antibody.” NCT07260591 ↗ |
| Modality | Vaccine | “VSV-02 Injection is an oncolytic virus vaccine” NCT07260591 ↗ |
| Route | Intravenous | “intratumoral (IT) injection followed by intravenous (IV) infusion” NCT07260591 ↗ |
| Route | Other | “intratumoral (IT) injection followed by intravenous (IV) infusion” NCT07260591 ↗ |